EMEA news from FierceBiotech
News
GSK bird flu vaccine wins race for European OK
After investing about $2 billion in development efforts, GlaxoSmithKline has won European approval for the first bird flu vaccine that can be used either in advance of or in the early days of a human Read more...
Pfizer rumored to be eyeing MediGene buyout
Rumors are swirling that Pfizer is looking to take over the German biotech Read more...
Developers: Politics behind slow approval process
Woodcock's defense, though, may seem particularly hard to accept at a slate of big pharma companies which have been able to win European approvals only to run straight into a roadblock at the U.S. Read more...
Canadian regulators forging new biosimilar pathway
While U.S. lawmakers jawbone about a regulatory pathway for biosimilars, or biogenerics, Read more...
Pharming shares sink after Rhucin gets thumbs down
There's new trouble for Pharming's Rhucin, an experimental treatment for hereditary angioedema. Pharming shares plunged after the company announced that the EMEA's Committee for Medicinal Products Read more...
ALSO NOTED: U.K. calls for halt to HIV study; Cadence to raise $49.3M; and much more...
> The U.K.'s Medical Research Council has advised Indevus Pharmaceuticals to close the high-dose arm of it's Phase III HIV study. Read more...
Cell Therapeutics reorganizes, scales back R&D
Cell Therapeutics is scaling back its research plans for Xyotax and pixantrone, cutting one group of Read more...
EMEA shoots down UBC's Cimzia
It looks like UBC has struck out in the EU. The EMEA told the company that the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on Cimzia, a treatment for Crohn's Read more...
Pharming raises $99M
Netherlands-based Pharming has raised $99 million (€70 million) through the issue of convertible bonds. The issue was managed by UBS Investment Bank. The company is also finalizing discussions for Read more...
ALSO NOTED: Novartis teams up with MIT; EMEA approves Galvus; and much more...
> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Read more...
Get more EMEA coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends